Cosmetic cross-reference

Docusate Sodium

CAS 577-11-7

Docusate Sodium (CAS 577-11-7) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 1,696 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
1,696
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Docusate Sodium
CAS Number
577-11-7
UNII
F05Q2T2JA0
InChIKey
APSBXTVYXVQYAB-UHFFFAOYSA-M
ChEMBL ID
CHEMBL1905872
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
DIETHYLHEXYL SODIUM SULFOSUCCINATE
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL1905872 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 36200.86 nM 9 -
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Drug ineffective 1153 629.077 10013709
Constipation 1746 624.161 10010774
Systemic lupus erythematosus 22 335.202 10042945
Pemphigus 8 334.452 10034280
Synovitis 17 318.64 10042868
Hand deformity 5 298.881 10061194
Completed suicide 67 240.286 10010144
Pneumonia aspiration 455 225.564 10035669
Maternal exposure during pregnancy 81 214.463 10071408
Glossodynia 50 214.149 10018388
Plasma cell myeloma 439 212.508 10035226
Contraindicated product administered 111 207.536 10078504
Arthropathy 134 193.322 10003285
Urinary tract infection 1160 191.334 10046571
Therapeutic product effect decreased 100 189.146 10082201
Gastrooesophageal reflux disease 602 187 10017885
Mental status changes 409 179.399 10048294
Discomfort 79 160.368 10013082
Pneumonia 2193 155.461 10035664
Duodenal ulcer perforation 5 154.844 10013849
Off label use 1439 154.489 10053762
Treatment failure 154 153.583 10066901
Death 2136 145.911 10011906
Alopecia 299 141.862 10001760
Pericarditis 56 135.159 10034484
Back pain 1147 130.53 10003988
Helicobacter infection 20 125.244 10054263
Joint swelling 349 123.228 10023232
Drug abuse 76 121.194 10013654
Dehydration 916 116.171 10012174
Drug intolerance 343 115.638 10061822
Deep vein thrombosis 547 114.385 10051055
Psoriatic arthropathy 33 114.213 10037162
Asthenia 1658 113.229 10003549
Toxicity to various agents 441 112.4 10070863
Pulmonary malformation 44 112.264 10037419
Wound 110 111.664 10052428
Pulmonary embolism 691 111.517 10037377
Intentional overdose 39 111.327 10022523
Muscle injury 5 110.463 10028314
Folliculitis 13 103.68 10016936
C-reactive protein increased 76 103.48 10006825
Fall 1555 103.405 10016173
Product use issue 265 97.472 10076309
Condition aggravated 695 94.202 10010264
Rheumatoid arthritis 268 93.887 10039073
Pleural effusion 575 93.788 10035598
Therapeutic product effect incomplete 117 92.253 10082200
Hypoxia 419 88.776 10021143
Somnolence 865 86.677 10041349

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 6 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
DIETHYLHEXYL SODIUM SULFOSUCCINATE 71722 SU MTHSPL
DOCUSATE SODIUM 71722 SU MTHSPL
Docusate Sodium 71722 SU MTHSPL
docusate sodium 71722 SU MTHSPL
Docusate sodium 71722 SU MTHSPL
docusate sodium 71722 PIN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Docusate Sodium used for in pharmaceutical contexts?

Docusate Sodium (CAS 577-11-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Docusate Sodium?

Docusate Sodium has 1,696 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug ineffective, Constipation, Systemic lupus erythematosus, Pemphigus, Synovitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Docusate Sodium also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Diethylhexyl Sodium Sulfosuccinate with EU status "permitted".

What clinical phase is Docusate Sodium in?

Docusate Sodium is rendered with ChEMBL max phase 3.